Phase 2b data from MindMed’s LSD-based therapy adds to the mounting evidence that psychedelic-assisted therapies could treat mental health conditions like anxiety, depression and PTSD. In particular, the study found statistically significant dose-dependent improvements in the Hamilton Anxiety rating scale (HAM-A) at the 100 and 200 μg dose levels in the four-week study. Similarly, recent…
Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies
Vancouver-based biotech firm BetterLife Pharma (OTCM:BETRF) is working on a non-hallucinogenic LSD derivative for treating neuropsychiatric and neurological disorders. Known as BETR-001 (2-bromo-LSD), the compound is also not controlled. Conversely, LSD, like other serotonergic hallucinogens, is a Schedule I compound. That status makes it difficult and expensive to research for potential medical uses. BetterLife announced…
LSD-assisted therapy resulted in durable anxiety improvement in Phase 2 study
A randomized placebo-controlled Phase 2 study found that lysergic acid diethylamide (LSD)–assisted therapy yielded significant reductions in anxiety and depression symptoms for up to 16 weeks. The data from the study was recently published in the peer-reviewed Biological Psychiatry. Researchers at the University Hospital Basel (UHB) conducted the investigator-initiated study, which involved 42 patients. While…
MindMed launches Phase 2b to study LSD in generalized anxiety disorder
Psychedelic medicine firm MindMed (Nasdaq: MNMD) has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD). The study will test the potential of LSD to treat generalized anxiety disorder (GAD), which affects about 3% of the population. While LSD emerged as the definitive psychedelic…